<p>Crescent Biopharma（纳斯达克代码：CBIO - 获取免费报告）于周四发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为（$4.93），低于市场共识预期的（$2.69），差距为（$2.24），据 Zacks 报道。</p>
<p>获取 <strong>Crescent Biopharma</strong> 的提醒：</p>
<h2>Crescent Biopharma 股价下跌 3.4%</h2>
<p>周五，CBIO 股票开盘价为 $12.00。该公司的市值为 $2.346 亿，市盈率为 -0.34，贝塔值为 1.51。Crescent Biopharma 的 52 周最低价为 $11.06，52 周最高价为 $63.00。</p>
<h2>华尔街分析师观点</h2>
<p>CBIO 一直是几份分析报告的主题。TD Cowen 在 6 月 20 日的报告中将 Crescent Biopharma 的评级上调至 “强力买入”。Wedbush 在 7 月 14 日的研究报告中开始覆盖 Crescent Biopharma，给予 “跑赢大盘” 评级，并设定 $27.00 的目标价。Wall Street Zen 在周六的研究报告中将 Crescent Biopharma 的评级从 “持有” 下调至 “卖出”。Lifesci Capital 在 6 月 18 日的研究报告中将 Crescent Biopharma 的评级上调至 “强力买入”，并设定 $22.00 的目标价。最后，Stifel Nicolaus 在 6 月 25 日的研究报告中开始覆盖 Crescent Biopharma，给予 “买入” 评级，并设定 $28.00 的目标价。一位股票研究分析师给予该股 “卖出” 评级，两位给予 “买入” 评级，两位给予 “强力买入” 评级。根据 MarketBeat 的数据，Crescent Biopharma 的共识评级为 “买入”，平均目标价为 $25.67。</p>
<p><strong>查看我们最新的 CBIO 股票分析</strong></p>
<h2>关于 Crescent Biopharma</h2>
<p>（获取免费报告）</p>
<p>Crescent Biopharma, Inc 是一家生物制药公司，开发和设计小分子治疗药物以治疗癌症。该公司成立于 2024 年 9 月 19 日，总部位于马萨诸塞州沃尔瑟姆。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Crescent Biopharma</li>
<li>2022-2025 年股票市场假期 - 纽约证券交易所和纳斯达克的休市时间</li>
<li>PG&amp;E 是 AI 的投资机会吗？为什么期权交易者在大举押注</li>
<li>投资者如何从盘后交易中受益</li>
<li>MarketBeat 周回顾 – 07/28 - 08/01</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>Hims &amp; Hers 会跟随诺和诺德下跌吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Crescent Biopharma 吗？</h2>
<p>在考虑 Crescent Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Crescent Biopharma 并不在名单上。</p>
<p>虽然 Crescent Biopharma 目前在分析师中获得 “强力买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CBIO

<p>Crescent Biopharma（纳斯达克代码：CBIO）报告的季度每股收益为（$4.93），低于市场共识预期的（$2.69），差距为（$2.24）。公告发布后，股价下跌 3.4%，开盘价为$12.00。该公司的市值为 2.346 亿美元，市场共识评级为 “买入”，平均目标价为$25.67。分析师的评级各不相同，其中有一项卖出评级、两项买入评级和两项强烈买入评级。Crescent Biopharma 专注于开发用于癌症治疗的小分子疗法</p>

<p>Crescent Biopharma (NASDAQ:CBIO - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($4.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.69) by ($2.24), Zacks reports.</p>
<div class="lb-trans"><p>Crescent Biopharma（纳斯达克代码：CBIO - 获取免费报告）于周四发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为（$4.93），低于市场共识预期的（$2.69），差距为（$2.24），据 Zacks 报道。</p>
</div><p>Get <strong>Crescent Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Crescent Biopharma</strong> 的提醒：</p>
</div><h2>Crescent Biopharma Stock Down 3.4%</h2>
<div class="lb-trans"><h2>Crescent Biopharma 股价下跌 3.4%</h2>
</div><p>Shares of CBIO stock opened at $12.00 on Friday. The company has a market capitalization of $234.60 million, a price-to-earnings ratio of -0.34 and a beta of 1.51. Crescent Biopharma has a fifty-two week low of $11.06 and a fifty-two week high of $63.00.</p>
<div class="lb-trans"><p>周五，CBIO 股票开盘价为 $12.00。该公司的市值为 $2.346 亿，市盈率为 -0.34，贝塔值为 1.51。Crescent Biopharma 的 52 周最低价为 $11.06，52 周最高价为 $63.00。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>CBIO has been the topic of several analyst reports. TD Cowen raised Crescent Biopharma to a &#34;strong-buy&#34; rating in a report on Friday, June 20th. Wedbush initiated coverage on Crescent Biopharma in a research note on Monday, July 14th. They issued an &#34;outperform&#34; rating and a $27.00 price objective on the stock. Wall Street Zen lowered Crescent Biopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Lifesci Capital raised Crescent Biopharma to a &#34;strong-buy&#34; rating and set a $22.00 price objective on the stock in a research note on Wednesday, June 18th. Finally, Stifel Nicolaus initiated coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They issued a &#34;buy&#34; rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Crescent Biopharma has a consensus rating of &#34;Buy&#34; and an average price target of $25.67.</p>
<div class="lb-trans"><p>CBIO 一直是几份分析报告的主题。TD Cowen 在 6 月 20 日的报告中将 Crescent Biopharma 的评级上调至 “强力买入”。Wedbush 在 7 月 14 日的研究报告中开始覆盖 Crescent Biopharma，给予 “跑赢大盘” 评级，并设定 $27.00 的目标价。Wall Street Zen 在周六的研究报告中将 Crescent Biopharma 的评级从 “持有” 下调至 “卖出”。Lifesci Capital 在 6 月 18 日的研究报告中将 Crescent Biopharma 的评级上调至 “强力买入”，并设定 $22.00 的目标价。最后，Stifel Nicolaus 在 6 月 25 日的研究报告中开始覆盖 Crescent Biopharma，给予 “买入” 评级，并设定 $28.00 的目标价。一位股票研究分析师给予该股 “卖出” 评级，两位给予 “买入” 评级，两位给予 “强力买入” 评级。根据 MarketBeat 的数据，Crescent Biopharma 的共识评级为 “买入”，平均目标价为 $25.67。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on CBIO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CBIO 股票分析</strong></p>
</div><h2>About Crescent Biopharma</h2>
<div class="lb-trans"><h2>关于 Crescent Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.</p>
<div class="lb-trans"><p>Crescent Biopharma, Inc 是一家生物制药公司，开发和设计小分子治疗药物以治疗癌症。该公司成立于 2024 年 9 月 19 日，总部位于马萨诸塞州沃尔瑟姆。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Crescent Biopharma</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Will Hims &amp; Hers Fall Along With Novo Nordisk?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Crescent Biopharma</li>
<li>2022-2025 年股票市场假期 - 纽约证券交易所和纳斯达克的休市时间</li>
<li>PG&amp;E 是 AI 的投资机会吗？为什么期权交易者在大举押注</li>
<li>投资者如何从盘后交易中受益</li>
<li>MarketBeat 周回顾 – 07/28 - 08/01</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>Hims &amp; Hers 会跟随诺和诺德下跌吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crescent Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Crescent Biopharma 吗？</h2>
</div><p>Before you consider Crescent Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Crescent Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Crescent Biopharma 并不在名单上。</p>
</div><p>While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Crescent Biopharma 目前在分析师中获得 “强力买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Crescent Biopharma（NASDAQ:CBIO）公布季度财报，每股收益比预期低 2.24 美元